No black box warning on record for Tafinlar

As of the latest FDA labeling reviewed, Tafinlar (DABRAFENIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Tafinlar medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS New Primary Malignancies, Cutaneous and Non-Cutaneous : Can occur when TAFINLAR is administered as a single agent or with trametinib. Monitor patients for new malignancies prior to, or while on therapy, and following discontinuation of treatment. ( 5.1 , 2.4 ) Tumor Promotion in BRAF Wild-type Tumors : Increased cell proliferation can occur with BRAF inhibitors. ( 5.2 ,

No black box warning on record for Tafinlar

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS New Primary Malignancies, Cutaneous and Non-Cutaneous : Can occur when TAFINLAR is administered as a single agent or with trametinib. Monitor patients for new malignancies prior to, or while on therapy, and following discontinuation of treatment. ( 5.1 , 2.4 ) Tumor Promotion in BRAF Wild-type Tumors : Increased cell proliferation can occur with BRAF inhibitors. ( 5.2 ,

Tafinlar Black Box Warning

No black box warning on record for Tafinlar

Other warnings & precautions

Tafinlar Black Box Warning

No black box warning on record for Tafinlar

Other warnings & precautions